Flatlander schreef op 13 november 2019 16:22:
From what I see of previous quarterly updates we will not get specific numbers of consoles and cartridges sold during the 3rd quarter. Rather they will provide adjustments to the outlook for 2019. That said I'm guessing at 335 consoles and 180,000 cartridges. More importantly I'm looking for news on the following:
Launching OncoDx Breast validation testing;
Announcement of Rapid Septicyte filing with the EU and FDA.
Announcement of China joint collaboration with Wondfu progress
Announcement of regulatory registration progress in Japan
Announcement of progress in proof of concept for OncoDx prostate.
Status of Gene fusion launch.
This is a significant number of catalysts that bode well for late 2020 and 2021. However, my expectations for 2nd half 2019 sales are muted. I think that these catalysts will lead to a ramp in sales in mid 2020 that will result in profitability in 2021.